Based on the research results of Professor Sang Sun Yoon’s laboratory at Yonsei University College of Medicine, BioMe Inc. was established as a faculty start-up with the aim of developing Live Biotherapeutic Products derived from human microbiome. • Through research over the past 10 years, we have secured a number of “Active Human Beneficial Bacteria” whose therapeutic efficacy has been verified. • We conducted research on the intestinal microbiome as well as the respiratory microbiome, and derived development pipelines for various indications including but not limited to: inflammatory bowel disease, infectious disease, cardiovascular disease, colorectal cancer, and dyslipidemia. • In addition, we have secured a number of isolates with new functions among the strains designated safe by the Ministry of Food and Drug Safety, and are developing jointly with domestic and foreign pharmaceutical and food companies. • Establishment of symBioMecollectionTM: Possessing a symbiotic microbiome library according to various lifestyles and health conditions (Over 400 people’s stool and saliva). Source material for identification of new beneficial bacteria. Joint research and development with lead pharmaceutical companies in progress.